After analyzing the genomes of more than one-quarter of a million military veterans, a team of scientists, led by researchers at University of California San Diego, Veterans Affairs San Diego Healthcare System (VASDHS), Yale University and West Haven VA, have identified 18 specific, fixed positions on chromosomes (known as loci) that appear associated with post-traumatic stress disorder (PTSD).
The findings validate the underlying biology of PTSD, its relationship to comorbid anxiety and depressive disorders and provide potential new targets for treatment, write the authors in the January 28, 2021 online issue of Nature Genetics.
Murray Stein, MD, MPH
“We’re very intrigued by the findings of this study, for example, as they pertain to the genetic relationships between different kinds of PTSD symptoms,” said co-principal investigator
Murray Stein, MD, MPH, Distinguished Professor of Psychiatry and Family Medicine and Public Health at UC San Diego School of Medicine and a psychiatrist at VASDHS. “It also shows the huge value of the Million Veteran Program in facilitating research important to the care of our military veterans.”
The research team conducted genome-wide association studies (GWAS) of more than 250,000 persons of European and African ancestry participating in the Million Veteran Program. GWAS involve rapidly scanning markers across complete sets of DNA, or genomes, of many people to find genetic variations associated with a particular disease. Launched in 2011, the Million Veteran Program is a U.S. Veteran Affairs-sponsored research effort to learn how genes, lifestyle and military exposures affect health and illness. More than 825,000 U.S. veterans have joined.
The scientists surveyed veterans’ electronic health records for diagnosed cases of PTSD and for quantitative symptoms, such as recurrent intrusive memories of traumatic events, severe emotional distress or physical reactions to reminders of traumatic events, self-destructive behaviors and difficulty sleeping.
PTSD is a serious mental disorder that can occur after exposure to extreme, life-threatening stress. It’s estimated that half to more than three-quarters of Americans experience traumatic events over a lifetime, but most do not develop PTSD. Lifetime prevalence for PTSD is approximately 7 percent (but much higher among veterans), which suggests people have varying degrees of resilience to stress and vulnerability to the disorder.
Susceptibility to PTSD has long been known to be heritable. Like other mental disorders, it is an extremely complex phenotype, or set of observable characteristics, that is influenced by multiple genes. Indeed, current diagnostic guidelines permit up to 163,120 unique conformations of symptoms for the disorder.
The study directly compared the heritability of diagnostic PTSD cases with continuous, symptom-based phenotypes of PTSD. Though symptoms of PTSD are extremely diverse, their genetic overlap is high — an important insight into the disorder’s underlying biology.
The researchers identified multiple genes that were repeatedly implicated in different PTSD phenotypes, indicating both that the genes were key players in development of the disorder and that they might be suitable targets for therapeutic drugs.
“These findings give us new insights into the biological basis of PTSD,” said co-principal investigator Joel Gelernter, MD, professor of psychiatry, genetics and neuroscience at Yale School of Medicine and VA Connecticut Healthcare System, “and point to some possible next steps for testing new treatments.”
Co-authors of the study include: Daniel F. Levey, Zhongshan Cheng, Frank R. Wendt, Gita A. Pathak, Mathew J. Girgenti, Ronald S. Duman, Renato Polimanti, Mihaela Aslan, Hongyu Zhao, John Concato and Joel Gelernter, all at VA Connecticut Healthcare System and Yale University; Kelly Harrington, VA Boston Healthcare System and Boston University School of Medicine; Kelly Cho, VA Boston Healthcare System and Brigham and Women’s Hospital; Rachel Quaden, Yuk-Lam Anne Ho and Daniel Posner, all at VA Boston Healthcare System; and Krishnan Radhakrishnan, VA Boston Healthcare System and University of Kentucky.
Funding support for this research came, in part, from the VA Cooperative Studies Program (CSP, no. CSP575B) and the Veterans Affairs Office of Research and Development MVP (grants MVP000 AND VA Merit MVP025).